Steven Morrison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steven Morrison has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- John T. Vetto
Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA
4 shared publications Graham Fowler
Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA
3 shared publicationsJonathan S. Zager
Department of Cutaneous Oncology(,) Moffitt Cancer Center, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, USA
3 shared publicationsDale Han
Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA
2 shared publicationsFaith Elenwa
Department of Epidemiology and Biostatistics, Texas A&M University, College Station, TX, USA
2 shared publicationsGang Han
Department of Epidemiology and Biostatistics, Texas A&M University, College Station, TX, USA
2 shared publications
Latest Publications
- 8 February 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 246, 116243
Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis
- 8 February 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 246, 116243
Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis
Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma?
Background: The significance of tumor‐infiltrating lymphocytes (TILs) in melanoma is debated. This article presents a multicenter, retrospective study assessing the predictive and prognostic value of TILs.Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with known TIL data. TILs were categorized as absent or present, which included nonbrisk (NB), brisk (B), and present but unspecified TIL levels. Clinicopathologic factors were correlated with TILs, sentinel lymph node (SLN) status, and melanoma‐specific survival (MSS).Results: Overall, 3203 patients were included. The median thickness was 1.5 mm, and 469 cases had SLN metastases. TILs were present in 2458 cases (76.7%), with NB, B, and unspecified TILs seen in 1691 (68.8%), 691 (28.1%), and 76 (3.1%), respectively. Multivariable analysis showed that the presence of TILs significantly predicted a negative SLN biopsy (P < .05). The median follow‐up was 25.2 months. MSS was significantly better for cases with TILs than cases without TILs (P < .001). According to multivariable analysis, age, gender, thickness, mitotic rate, ulceration, lymphovascular invasion, and SLN status were significantly prognostic of MSS (all P values < .05). Although TILs were not prognostic of MSS, when multiple imputation was used and the SLN status was excluded, the presence of TILs was significantly prognostic of improved MSS (hazard ratio, 0.78; 95% confidence interval, 0.64‐0.95; P = .0154).Conclusions: TILs are a favorable marker because their presence significantly predicts a negative SLN, and the absence of TILs may be a prognostic marker of worse survival in patients with a positive SLN but not a negative SLN. TILs may also serve as a prognostic marker of survival when the SLN status is not considered.
Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma?
Background: The significance of tumor‐infiltrating lymphocytes (TILs) in melanoma is debated. This article presents a multicenter, retrospective study assessing the predictive and prognostic value of TILs.Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with known TIL data. TILs were categorized as absent or present, which included nonbrisk (NB), brisk (B), and present but unspecified TIL levels. Clinicopathologic factors were correlated with TILs, sentinel lymph node (SLN) status, and melanoma‐specific survival (MSS).Results: Overall, 3203 patients were included. The median thickness was 1.5 mm, and 469 cases had SLN metastases. TILs were present in 2458 cases (76.7%), with NB, B, and unspecified TILs seen in 1691 (68.8%), 691 (28.1%), and 76 (3.1%), respectively. Multivariable analysis showed that the presence of TILs significantly predicted a negative SLN biopsy (P < .05). The median follow‐up was 25.2 months. MSS was significantly better for cases with TILs than cases without TILs (P < .001). According to multivariable analysis, age, gender, thickness, mitotic rate, ulceration, lymphovascular invasion, and SLN status were significantly prognostic of MSS (all P values < .05). Although TILs were not prognostic of MSS, when multiple imputation was used and the SLN status was excluded, the presence of TILs was significantly prognostic of improved MSS (hazard ratio, 0.78; 95% confidence interval, 0.64‐0.95; P = .0154).Conclusions: TILs are a favorable marker because their presence significantly predicts a negative SLN, and the absence of TILs may be a prognostic marker of worse survival in patients with a positive SLN but not a negative SLN. TILs may also serve as a prognostic marker of survival when the SLN status is not considered.
- 21 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 2867-2868
ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?
- 21 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 2867-2868
ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?
- 17 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 1-2
ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?
- 17 January 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (5) , 1-2
ASO Visual Abstract: Is There a Relationship Between Tumor-Infiltrating Lymphocytes (TILs) and Regression in Melanoma?
- Open Access
- 27 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 838-840
Improvement of primary vulvar Langerhans cell histiocytosis with lenalidomide
- 27 September 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 838-840
Open AccessImprovement of primary vulvar Langerhans cell histiocytosis with lenalidomide